|Drug class||Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor|
AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder. It was also under development for anxiety disorders, but development for this indication was discontinued. The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.
- "Initiator Pharma".
- Shao L, Li W, Xie Q, Yin H (2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opin Ther Pat. 24 (2): 131–54. doi:10.1517/13543776.2014.859676. PMID 24289044. S2CID 1825304.
- Gerhard F. Ecker; Rasmus P. Clausen; Harald H. Sitte (16 December 2016). Transporters as Drug Targets. Wiley. pp. 36–. ISBN 978-3-527-67951-5.
- "Initiator Pharma signs option agreement for Phase 2 ready drug candidate". News Powered by Cision. Retrieved 2022-02-08.